Page 33 - Read Online

Li et al. Hepatoma Res 2020;6:15 I http://dx.doi.org/10.20517/2394-5079.2019.34 Page 11 of 13

recurrence in hepatocellular carcinoma patients. Int J Cancer 2011;128:887-96.
67. Kuang DM, Xiao X, Zhao Q, Chen MM, Li XF, et al. B7-H1-expressing antigen-presenting cells mediate polarization of
protumorigenic Th22 subsets. J Clin Invest 2014;124:4657-67.
68. Xia Y, Chen R, Ye SL, Sun R, Chen J, et al. Inhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration
and invasion of hepatocellular carcinoma. Clin Exp Metastasis 2011;28:661-74.
69. He G, Zhang H, Zhou J, Wang B, Chen Y, et al. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1
signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2015;34:141.
70. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
71. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma
previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
72. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, et al. Pembrolizumab as second-line therapy in patients with advanced
hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial. J Clin Oncol 2020;38:193-202.
73. Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for
hepatocellular carcinoma. J Hepatol 2020;72:307-19.
74. Floudas CS, Brar G, Greten TF. Immunotherapy: current status and future perspectives. Dig Dis Sci 2019;64:1030-40.
75. Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung
cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-
label phase 3 trial. Lancet Respir Med 2019;7:387-401.
76. Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, et al. Ramucirumab as second-line treatment in patients with
advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised
phase III REACH study. Eur J Cancer 2017;81:17-25.
77. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med
1995;182:459-65.
78. Liu Z, Song Z, Sun J, Sun F, Li C, et al. Association between CTLA-4 rs231775 polymorphism and hepatocellular carcinoma
susceptibility. Int J Clin Exp Pathol 2015;8:15118-22.
79. Chen X, Du Y, Hu Q, Huang Z. Tumor-derived CD4 CD25 regulatory T cells inhibit dendritic cells function by CTLA-4. Pathol Res
+
+
Pract 2017;213:245-9.
+
+
80. Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, et al. Human CD14 CTLA-4 regulatory dendritic cells suppress T-cell response by cytotoxic
T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology
2014;59:567-79.
81. Pedroza-Gonzalez A, Zhou G, Singh SP, Boor PP, Pan Q, et al. GITR engagement in combination with CTLA-4 blockade completely
abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo. Oncoimmunology 2015;4:e1051297.
82. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab
in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
83. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, et al. Tremelimumab in combination with ablation in
patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51.
84. Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients
(pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J Clin Oncol 2019;37:4012.
85. Kaseb A, Vence L, Blando J, Yadav S, Ikoma N, et al. Randomized, open-label, perioperative phase II study evaluating nivolumab
alone versus nivolumab plus ipilimumab in patients with resectable HCC. Ann Oncol 2019;30:iv112.
86. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung
cancer. N Engl J Med 2019;381:2020-31.
87. Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther
2009;8:2211-20.
88. Cariani E, Missale G. KIR/HLA immunogenetic background influences the evolution of hepatocellular carcinoma. Oncoimmunology
2013;2:e26622.
89. Pan N, Qiu J, Sun H, Miao F, Shi Q, et al. Combination of human leukocyte antigen and killer cell immunoglobulin-like receptor
genetic background influences the onset age of hepatocellular carcinoma in male patients with hepatitis B virus infection. Clin Dev
Immunol 2013;2013:874514.
90. Vey N, Karlin L, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, et al. A phase 1 study of lirilumab (antibody against killer
immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. Oncotarget
2018;9:17675-88.
91. Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, et al. A phase 1 trial of the anti-KIR antibody
IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012;120:4324-33.
92. van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, et al. NKG2A blockade potentiates CD8 T cell immunity induced by
cancer vaccines. Cell 2018;175:1744-55.e15.
93. Xu HC, Huang J, Pandyra AA, Lang E, Zhuang Y, et al. Lymphocytes negatively regulate NK cell activity via Qa-1b following viral
infection. Cell Rep 2017;21:2528-40.
94. André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor
immunity by unleashing both T and NK cells. Cell 2018;175:1731-43.e13.
95. Kamiya T, Seow SV, Wong D, Robinson M, Campana D. Blocking expression of inhibitory receptor NKG2A overcomes tumor
resistance to NK cells. J Clin Invest 2019;129:2094-106.